USP's Work Plan and New Revision Approaches - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

USP's Work Plan and New Revision Approaches
Following its 2005 Convention, USP is adopting new approaches to develop monographs and products and to carry out the organization's ambitious work plans.

Pharmaceutical Technology

Revised processes and new approaches

The July–August 2006 PF Policies and Announcements column included "Recent Modifications to the USP Standards-Setting Process," a notice that USP's Council of Experts approved changes to its Rules and Procedures to expedite the monograph approval process and to expand the scope of the monographs that USP publishes (6). These changes were effective Sept. 1, 2006.

New authority to evaluate comments. One provision in particular is designed to reinforce the ability of an Expert Committee to finalize and approve revisions to USP–NF without republication in PF. Previously, any change made to a proposed revision published in PF automatically triggered republication of the monograph in PF, frequently necessitating multiple publication cycles. In some cases, second-entry manufacturers complained that the system was being exploited to delay approval of their monograph and, thus, entry of their product into the US marketplace.

Under the new provision, an Expert Committee will be given authority to evaluate comments on their scientific merits, to modify the submitted monograph if supporting scientific and validation information so warrant, and to move the monograph to official status in the next Interim Revision Announcement, Supplement, or USP–NF. The Expert Committee would be required to summarize and respond to public comments about the revision, much like the comment and response section at the beginning of Federal Register notices. In other words, the current Briefings that introduce monograph revisions in PF would be greatly expanded and would be more informational.

An essential point is that the Expert Committee will be allowed to decide whether it has sufficient information to modify the draft monograph if necessary and make it official or to send it back to PF for another round of public review and comments. In either case, the Expert Committee, as always, will make its decisions based on sound scientific principles.

Communicating changes. Expert Committees also will use the USP Web site and other vehicles more extensively to communicate proposed revisions. In addition, the revised Rules and Procedures allow a new group, FDA Observers, to more fully participate in USP Expert Committee meetings. Once confidentiality issues have been resolved, FDA Observers can contribute their compendial and scientific knowledge to the monograph review process.

These changes will expedite monograph development and approvals, but USP again emphasizes that Expert Committees always have the option to republish monographs in PF for further public review when the circumstances warrant. USP believes that speeding up approvals should not impose a compliance burden on industry, and, thus, the implementation period between publication of new monographs and revisions and the date on which they become official generally is being expanded to six months. Each issue of PF contains a chart indicating the dates on which comments are due, the targeted official publication, the latter's date of publication, and the official date.

New ways to develop monographs. In addition to revising its processes, USP is expanding the approaches used to acquire and develop monographs. For example, USP is developing procedures to identify monographs that are published in other major pharmacopeias of the world but not in USP–NF. Some of these candidate monographs may be submitted to the Council of Experts for review and possible adoption as alternative-source monographs. USP's Monograph and Reference Standards Development Department will work with partners whenever possible to conduct inter- and intra-laboratory collaborative tests using sound metrological procedures to evaluate candidate reference standard materials as appropriate. USP's new office in India will collaborate and may help provide candidate reference standards for articles approved as generics in the United States.

USP also is undertaking the development of monographs for medicines pending approval at FDA (Standards for Articles Pending FDA Approval or SAPFA) so that such monographs can be made available and official upon FDA approval. Before FDA approval, a SAPFA monograph will be posted on USP's Web site, but once approval is granted (and FDA is allowed an opportunity to comment on the monograph), it will be moved to USP–NF and have official status.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here